Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis by Masaki Ujihara et al.
Ujihara et al. BMC Research Notes 2013, 6:210
http://www.biomedcentral.com/1756-0500/6/210RESEARCH ARTICLE Open AccessImportance of appropriate pharmaceutical
management in pregnant women with
ulcerative colitis
Masaki Ujihara1, Takafumi Ando1*, Kazuhiro Ishiguro1, Osamu Maeda1, Osamu Watanabe1, Yutaka Hirayama1,
Kazuhiro Morise1, Keiko Maeda1, Masanobu Matsushita1, Ryoji Miyahara1, Naoki Ohmiya1, Yuji Nishio2,
Takeo Yamaguchi3, Jun-ichi Haruta3, Kenji Ina4 and Hidemi Goto1Abstract
Background: Ulcerative colitis (UC) often occurs in women of childbearing age. Compared to Western countries,
however, few studies have investigated the impact of UC on the progress of pregnancy in Asian populations.
Methods: We retrospectively examined 91 pregnancies in 64 patients with UC experienced at our hospital and
related institutions from 1991 to 2011, focusing on the relationship between the progression of UC during
pregnancy, progress of the pregnancy itself, and the treatment of UC.
Results: In 80 of 91 pregnancies the patient had already been diagnosed with UC at the time she became
pregnant, of whom 31 (38.8%) experienced exacerbation during pregnancy. Regarding severity, moderate or severe
active-stage disease during pregnancy was seen in 13.7% of those who had been in remission at the onset of
pregnancy versus 58.6% of those who had been in the active stage at onset (OR 8.9: 95%CI 3.0~26.4; P<0.01). The
incidence of miscarriage or abortion was 9.8% in pregnancies in which UC was in remission at onset versus 31% in
those in which it was in the active stage at onset (OR 4.1: 95%CI 1.2~13.9; P=0.02). Among patients, 62.5% were
receiving pharmaceutical treatment at onset of pregnancy. Exacerbation during pregnancy occurred in 26.5% of the
group who continued to receive the same treatment during pregnancy versus 56.3% of those with a dose decrease
or discontinuation after onset (OR 3.6: 95%CI 1.0~12.4; P=0.04).
Conclusions: UC patients wishing to conceive should do so when in remission and continue appropriate
pharmaceutical treatment during pregnancy.
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Recent reports suggest that the number of patients with
ulcerative colitis (UC) has continued to increase steadily
in East Asia [1-6]. Onset of UC typically occurs during
adulthood, affecting individuals during their reproduct-
ive years. Patients with UC want to know whether dis-
ease activity and medical treatment exert any influence
on their fertility, pregnancy, and babies. While several
reports on the effects of UC on the course of preg-
nancy have appeared from Europe and the US [7-12],* Correspondence: takafumiando-gi@umin.ac.jp
1Department of Gastroenterology and Hepatology, Nagoya University
Graduate School of Medicine, Nagoya 466-8550, Japan
Full list of author information is available at the end of the article
© 2013 Ujihara et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the oronly a few studies have been reported from Asia [13,14].
In particular, information regarding disease activity and
medication is scarce, because these investigations are not
easily conducted. Vermeire et al. [15] suggested that cli-
nicians should ensure therapy compliance by discussing
with patients the need for drug therapy to maintain
remission, and should mention that most drugs for in-
flammatory bowel disease (IBD) are compatible with
pregnancy. ECCO [10] also reported that in the major-
ity of patients, the maintenance of remission with med-
ical treatment outweighs the potential risks of adverse
drug effects.
At present, the relationship between pregnancy and
UC has not been well investigated in Asian countries.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from UC patients in Western countries may be useful in
the management of UC patients in Japan, clinical condi-
tions of UC in Asians show important differences from
those in Caucasians [16-18]. For example, the severity of
UC in Asian patients is relatively mild, with few cases re-
quiring surgery and low mortality rates [16]. Further-
more, genetic backgrounds and environmental factors
influencing UC differ between Asian and western coun-
tries. These differences highlight the need for research
into the interrelation of UC course, treatment, and preg-
nancy in Asian populations.
To better characterize the relationship of pregnancy
and UC in Japan, we have focused on disease activity
and medical treatment during pregnancy. Here, we
conducted a retrospective clinical examination of the
course of pregnancies experienced by patients with UC
at our hospital and related facilities.
Methods
Subjects
With approval by the ethics committee of each institu-
tion (Nagoya University Graduate School of Medicine,
Meitetsu Hospital, and Nagoya First Red Cross Hos-
pital), we retrospectively examined 91 pregnancies in
64 UC patients (Table 1, Figure 1) experienced at our
hospital and related institutions from 1991 to 2011,
focusing on the relation between the progression of
UC during pregnancy, the course of the pregnancy it-
self, and the treatment of UC. At each institution,
when a UC patient became pregnant, her doctor
reported her name for addition to our list. We investi-
gated the effects of pregnancy on the course of UC by
reviewing the medical records of the patients entered
into the list.Table 1 Characteristics of patients
Sixty-four patients
Mean ± SD Outcome of preg
Age at diagnosis (years) 23.95±5.56
Disease duration (years) 7.22±6.21
Age at pregnancy (years) 32.25±4.36
Extent of UC n (%) Receiving treatmen
Total colitis 30 (46.9) at the onset of pre
Left-side colitis 22 (34.4)
Proctitis 12 (18.7)
Clinical course n (%)
Relapsing-remitting type 53 (82.8)
Cronic continuous type 6 (9.4)
Acute fulminating type 1 (1.6)
First attack type 4 (6.2)Study protocol
The medical records of the patients were reviewed by
a primary investigator (M.U.), who graded the severity
of UC according to the criteria of the Truelove-Witts
index [19], namely as remission, mild, moderately severe
(moderate), and severe. Assessment was done at the on-
set of pregnancy and at the worst point during the preg-
nancy. Exacerbation of UC was categorized as a further
worsening of severity from that at the onset of preg-
nancy. The first trimester was considered the first 14
weeks of pregnancy, the second trimester from week 15
to 27, the third trimester from week 28 until birth, and
the postnatal period was the first 8 weeks following birth.
Statistical analysis
Statistical analysis was performed using the chi-square
test or Fisher’s exact test using SPSS Statistics Version 19
(Chicago, IL). Odds ratio (OR) and 95% confidence inter-
val (CI) were estimated when appropriate. All P values
were two-tailed, and significance level was set at P<0.05.
Results
Patients
Patient characteristics are shown in Table 1. Among the
91 pregnancies, UC had already been diagnosed at onset
in 80 cases, of which 51 were in remission, 19 were mild,
10 were moderately severe, and no cases were severe
(Figure 1).
Course of pregnancy
Among the 80 pregnancies in which UC had been already
diagnosed at the onset of pregnancy, exacerbation of UC
was identified in 31 (23 of 51 in remission at onset of preg-
nancy (45.1%), and 8 of 29 with active disease at onset
(27.6%)) (Figures 1 and 2, Table 2). When we examined theNinety-one pregnancies (%)
nancy normal birth 73 (80.2)
premature birth 2 (2.2)
spontaneous abortion 8 (8.8)
therapeutic termination 8 (8.8)
t for UC
gnancy total (n=80) 50 (62.5)
salazosulfapyridine (SASP) 20 (40)
5-aminosalicylic acid
compound (5-ASA) 19 (38)




Figure 1 Schema of the severity at the onset of pregnancy and change in severity during pregnancy. Green squares indicate UC diagnosis and
status at the onset of pregnancy, and blue squares indicate UC status during pregnancy. Cases experiencing exacerbation are shown in red.
Figure 2 Schema of the frequency of exacerbation of UC during pregnancy by approach to treatment. Green squares indicate UC treatment at
the onset of pregnancy, and blue squares indicate UC treatment during pregnancy. Cases experiencing exacerbation are shown in red.
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Table 2 Incidence of exacerbation and miscarriages or abortions during pregnancy
At the onset of pregnancy Remission Active OR 95%CI P value
n=51 (%) n=29 (%)
During pregnancy
Exacerbation 23 (45.1) 8 (27.6) 0.46 0.2~1.2 N. S
Exacerbation to severe or moderately severe 7 (13.7) 17 (58.6) 8.9 3.0~26.4 <0.01
Miscarriage or abortion 5 (9.8) 9 (31) 4.1 1.2~13.9 0.02
Figure 3 Exacerbation rate of UC by approach to treatment.
Exacerbation rate was significantly higher in patients whose doses
were reduced or whose treatment was discontinued than in those
who continued pharmaceutical treatment.
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worst point during pregnancy, 7 of 51 cases (13.7%) were
in pregnancies in patients in remission at the onset of preg-
nancy, whereas 17 of 29 (58.6%) were in pregnancies in pa-
tients with active disease at the onset of pregnancy; hence,
moderate or severe active stage disease at the worst point
was significantly more frequent in pregnancies in the active
stage at the onset of pregnancy (OR 8.9: 95%CI 3.0~26.4;
P<0.01) (Table 2). With regard to the period of exacerba-
tion of UC, 24 cases experienced exacerbation during the
first trimester, 8 during the second, 3 during the third, and
7 during the puerperal period (not including second cases
of exacerbation in the same patient), with the first trimes-
ter and puerperal period together accounting for 73.8%.
Outcome of the 91 pregnancies was as follows: 73 normal
births (80.2%), 2 premature births (2.2%), 8 miscarriages
(8.8%), and 8 abortions (8.8%). Miscarriages and abortions
occurred in 5 of the 51 pregnancies (9.8%) in patients in re-
mission at the onset of pregnancy, and in 9 of the 29 preg-
nancies (31.0%) with active stage disease at the onset of
pregnancy (OR 4.1: 95%CI 1.2~13.9; P=0.02) (Table 2).
UC treatment during pregnancy
Among the 80 cases who had already been diagnosed
with UC at the onset of pregnancy, 50 (62.5%) were
receiving treatment for UC at the onset of pregnancy
(Table 1, Figure 2), consisting of salazosulfapyridine
(SASP) in 20, 5-aminosalicylic acid compound (5-ASA)
in 19, SASP and corticosteroids in 5, 5-ASA and cortico-
steroids in 3, corticosteroids only in 2, and 5-ASA and
azathioprine in 1. Sixteen of the 50 cases (32.0%) receiv-
ing treatment for UC at the onset of pregnancy were
treated with a decrease in dosage or cessation of treat-
ment during pregnancy. Regarding outcome, exacerba-
tion of UC was found in 9 of 34 pregnancies (26.5%) in
which the same treatment was maintained during preg-
nancy, and in 9 of 16 pregnancies (56.3%) in which doses
were reduced or treatment was discontinued (OR 3.6:
95%CI 1.0~12.4; P=0.04), while 13 of 30 cases (43.3%)
that had not been treated at the onset of pregnancy ex-
perienced exacerbation (Figures 2, 3). Next, we com-
pared UC course among patients whose UC had been in
remission at the onset of pregnancy. For the 25 pregnan-
cies in patients who had been receiving treatment andwere in remission at the onset of pregnancy, exacerba-
tion of UC occurred in 5 of 16 pregnancies (31.3%) in
which the same treatment was continued, and in 6 of 9
pregnancies (66.7%) in which doses were reduced or
treatment was discontinued during pregnancy; while for
the 26 pregnancies in patients who had not been receiv-
ing treatment and were in remission at the onset of
pregnancy, exacerbation of UC occurred 12 pregnancies
(46.2%) (Figure 4). Patients in whom doses had been re-
duced or treatment had been discontinued were thus
most likely to experience exacerbation, albeit that the
differences were not significantly different.
Patients with newly developed UC
Regarding the 11 patients who newly developed UC dur-
ing pregnancy, severity was mild in 5 (45.5%), moderate
Figure 4 Exacerbation rate in patients in remission at the onset
of pregnancy by approach to treatment.
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were proctitis (45.5%) and six were pancolitis (54.5%).
Most occurrences were identified during the early period
of pregnancy, with six occurring during the first trimes-
ter (54.5%).
Newborns status
Deformities and complications in newborns were identi-
fied in 2 of 75 births (2.7%), including 1 case of cleft
palate. This patient was in remission at the onset of
pregnancy, experienced exacerbation to moderate active
stage disease during the first trimester, but had a nor-
mal delivery. The baby of the second patient, who was
also in remission at the onset of pregnancy but did not
experience exacerbation, showed prolonged jaundice
but also had a normal delivery. Both patients were
treated with 5-ASA during pregnancy.
Discussion
Here, we found that the frequency of exacerbation to the
moderate or severe active stage during pregnancy in pa-
tients who were in the active stage at the onset of preg-
nancy was significantly higher than in those who had been
in remission at the onset of pregnancy. Further, patients
who were treated by a decrease in dosage or cessation of
treatment during pregnancy showed a significantly higher
exacerbation ratio than those in whom treatment at theonset of pregnancy was maintained during pregnancy.
These findings suggest that women with UC who wish to
conceive should be advised to do so while in remission ra-
ther than in the active stage, and continue appropriate
treatment during pregnancy.
Exacerbation rates of UC were 45.1% for patients in
remission at the onset of pregnancy. Alstead [20] has
shown that if conception occurs during a period of re-
mission, about one-third of patients with IBD will re-
lapse during pregnancy. In our study, the exacerbation
ratio of patients in remission at onset tended to be
higher than in their report, however, the exacerbation of
UC in remission was mostly to the mild active stage.
The frequency of exacerbation to the moderate or severe
active stage during pregnancy in patients who were in
the active stage at the onset of pregnancy was signifi-
cantly higher than in those who had been in remission
at the onset of pregnancy (58.6% vs 13.7%). We therefore
propose that patients with UC who wish to become
pregnant should do so when they are in remission.
With regard to the timing of exacerbation, 57.1% of
our cases with exacerbation occurred during the first tri-
mester. Miller [21] also reported that exacerbation was
most likely to occur in the first trimester. We assume
that exacerbation during this period is caused by stress,
such as morning sickness. Moreover, many of our pa-
tients had a decrease in dosage or cessation of treatment
during the first trimester, and we consider that some
women are reluctant to receive medication during preg-
nancy. Ferrero et al. [22] emphasized that the exacerba-
tion of IBD during pregnancy, particularly during the
first trimester, is often due to the discontinuation of
maintenance medication. These findings highlight the
need for careful observation of UC patients during the
first trimester.
The outcome of pregnancy in this series was normal
birth in 80.2%, miscarriage or abortion in 17.6% and
congenital malformation in 1.1%. Naganuma et al. [15]
reported rates of 82.9% for live birth, 16.2% for spontan-
eous and therapeutic abortion, and 1.3% for congenital
malformation in Japanese patients with UC. These re-
sults are similar to those of our study. In contrast,
Hanan et al. [23] reported rates of 76%-97% for normal
birth, 1%-13% for miscarriage, and 0%-3% for stillbirth.
They also observed congenital abnormalities in 0%-3%,
which was not significantly different from that of the
non-UC controls. Recently Bortoli et al. [24] reported
rates of 94.7% for normal birth and 5.3% for miscarriage
or abortion, which were also not significantly different
from that of the non-UC controls. In our study, miscar-
riage or abortion occurred in 9.8% of pregnant UC
patients who had been in remission at the onset of preg-
nancy versus 31% of those who had been in the active
stage at onset, and was therefore significantly higher
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nancy. The tendency of miscarriage or abortion appeared
to decrease with time, indicating the need for a prospective
study of pregnant women with UC in Japan.
Our study identified 11 occurrences of newly arising UC
during pregnancy. Onset was most frequent during the
first trimester, and severity was mostly moderate or severe.
Willoughby et al. [25] reported that 8 of 16 patients had
their first attack of UC in the first trimester, and that the
first attack in the 3 of 4 patients with severe disease oc-
curred in the first trimester. These findings suggest that pa-
tients with the new onset of UC during pregnancy tend to
then experience exacerbation to a more severe degree, and
accordingly require more stringent therapy.
In this study, 62.5% of patients were under pharma-
ceutical treatment at the onset of pregnancy. Drugs such
as SASP, 5-ASA and corticosteroids are categorized
as Food and Drug Administration (FDA) pregnancy-
category-B drugs, and as safe drugs by the European
Panel on the Appropriateness of Crohn's Disease
Therapy (EPACT) and the ECCO [8,10]. In Japan,
the Ministry of Health, Labour and Welfare has de-
clared immunoregulators to be contraindicated for
use in pregnant women, and we found only one patient
who used an immunoregulator for UC during preg-
nancy in our study. This patient became pregnant in
remission, did not experience exacerbation during
pregnancy, and gave birth without complications. The
ECCO classifies azathioprine and 6-mercaptopurine as
safe [10]. The EPACT classifies these drugs as having
equivocal safety during the first trimester and nursing,
and as safe drugs during the second and third trimes-
ters [8], while the FDA classifies them as category-D.
These reports suggest that immunoregulators might be
safe, but should be used cautiously in patients with UC
who become pregnant with full discussion of the ad-
vantages and risks of their use.
The exacerbation rate in UC patients for whom doses
were reduced or treatment was discontinued during
pregnancy was significantly higher than in those who
maintained the same pharmaceutical treatment as before
pregnancy. Among patients in the three groups who
were in remission at the onset of pregnancy, the lowest
exacerbation rate was seen in patients who maintained
the same pharmaceutical treatment while the highest
rate was seen in patients for whom doses were reduced
or treatment was discontinued during pregnancy, albeit
that the differences were not statistically significant
owing to the small sample size and limited statistical
power of this study (Figure 4). In their meta-analysis of
pregnancy outcomes in women with IBD following ex-
posure to 5-ASA (including SASP) drugs, Rahimi R
et al. [26] reported a no greater than 1.14-fold increase
in spontaneous abortion, and a 1.16-fold increase incongenital abnormalities. It is safe and important to con-
tinue proper maintenance therapy during pregnancy.
Several limitations of our study warrant mention. The
retrospective design of the study may have introduced a
degree of selection bias. Because we collected our data
from medical records, we were unable to verify all infor-
mation about the mode of delivery and exact weight of
babies. Comparisons were also hampered by the range
of patient treatments and instructions among institu-
tions and doctors. Further prospective studies with an
increased number of pregnant UC patients are therefore
required.
Conclusions
This study shows that the impact of UC on the progress of
pregnancy does not widely differ between Japanese and
Western patients. UC patients wishing to become pregnant
should be advised to do so while they are in the remission
stage, and to continue appropriate pharmaceutical treat-
ment during pregnancy.
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